A Pilot Study Assessing Intra-Metastasis Administration of Autologous KLH-pulsed Dendritic Cells With Tumoral Radiation Therapy in Patients With Metastatic Pancreatic Carcinoma

NCT ID: NCT00843830

Last Updated: 2015-12-08

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1
• Total Enrollment: 4 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-10-31
• Study Completion Date: 2010-04-30

Brief Summary

This study is being done to determine whether it is possible to use an investigational vaccine that consists of dendritic cells in patients with pancreas cancer. Dendritic cells are immune cells that are obtained from your blood that are important in the body's immune response to foreign substances. The vaccine would be injected directly into a tumor that has spread to the liver after a short course of radiation therapy has been given to that tumor. The study will try to determine if this treatment would be safe and effective in treating this cancer.

This is a phase 1 pilot study of this treatment. Phase 1 trials test the best way to give a treatment where little is known about its possible risks or benefits. Phase 2 studies then test the possible benefits of a treatment and may show the specific situations where they are seen. Promising treatments are then tested in Phase 3 trials which compare the new treatment to standard treatment in a larger group of patients. Phase 4 trials are those conducted on a treatment after it has been approved for general use outside of research. A pilot study tests a treatment in a small number of patients to learn if and how the treatment could be tested in a larger group. Pilot studies can be performed at any phase but are commonly performed in the earliest phases of research on a treatment.

Conditions

Metastatic Pancreatic Carcinoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Treatment Arm

Participants will receive tumoral irradiation and dendritic cell vaccination.

Group Type: EXPERIMENTAL

tumoral irradiation

Intervention Type: RADIATION

On day 1 of the study treatment, patients will begin tumoral irradiation, which will be given daily for 4 days in 6Gy fractions (days 1 through 4)

Dendritic cell vaccination

Intervention Type: BIOLOGICAL

Three intra-tumoral injections of 1 ml cell suspensions of KLH (keyhole limpet hemocyanin)- pulsed DC (dendritic cells) will be delivered percutaneously under ultrasound into a selected hepatic metastasis in the outpatient setting.

Interventions

tumoral irradiation

On day 1 of the study treatment, patients will begin tumoral irradiation, which will be given daily for 4 days in 6Gy fractions (days 1 through 4)

Intervention Type: RADIATION

Dendritic cell vaccination

Three intra-tumoral injections of 1 ml cell suspensions of KLH (keyhole limpet hemocyanin)- pulsed DC (dendritic cells) will be delivered percutaneously under ultrasound into a selected hepatic metastasis in the outpatient setting.

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• Pathologic diagnosis of pancreatic carcinoma
• Radiologic evidence of hepatic metastasis with at least one lesion > 2.0 cm that is amenable to ultrasound or CT guided intra-tumoral DC injection
• Age > 18
• Life expectancy > 3 months
• Karnofsky Performance Status > 70%
• Patients must not have received any anti-neoplastic chemotherapy, immunotherapy or radiotherapy for the four weeks preceding entry onto the study (six weeks for nitrosoureas and mitomycin C).
• Adequate baseline hematopoietic function defined as WBC (white blood cell) > 3000/mm3, hemoglobin > 9g/dl, and platelet count > 100,000/mm3.
• Adequate baseline organ function defined as creatinine < 2.0, total bilirubin < 2.0 mg/dl
• Patients taking warfarin are not eligible. Adequate coagulation function defined as PT (prothrombin time) < 15, INR < 1.5 and PTT (partial thromboplastin time) < 35.
• Ability to give informed consent

Exclusion Criteria

• Previous anti-tumor vaccine therapy
• Prior hepatic irradiation
• Known brain metastases
• History of prior autoimmune diseases (e.g. SLE (systemic lupus erythematosus), rheumatoid arthritis, myasthenia gravis)
• Regular corticosteroid use within the past one year or any corticosteroid use in the four weeks preceding study entry
• Evidence of HIV infection, AIDS, Hepatitis B or Hepatitis C infection
• Active bacterial, fungal or viral infection
• Pregnancy or lactation; women of childbearing potential and men must agree to use effective contraception during the course of this clinical trial
• Uncontrolled or unstable medical conditions including angina, arrhythmias, bleeding, or thromboembolic conditions,
• Any medical or psychiatric illness that might compromise the patients ability to tolerate treatment

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Michigan Rogel Cancer Center

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Mark M. Zalupski, M.D.

Role: PRINCIPAL_INVESTIGATOR

Universtiy of Michigan Comprehensive Cancer Center

Locations

Universtiy of Michigan Comprehensive Cancer Center

Ann Arbor, Michigan, United States

Countries

United States

Other Identifiers

UMCC 2005.135

Identifier Type: -

Identifier Source: org_study_id